Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaochun Ji
Institution:
Ningbo Medical Center Lihuili Hospital
Observed institutions:
Ningbo University,
Ningbo Medical Center Lihuili Hospital
ORCID:
0000-0002-4771-5017
Observed ORCID:
0000-0002-4771-5017
OpenAlex ID:
A5101483370
Hypermethylated KLF9 Is An Independent Prognostic Factor For Favorable Outcome In Breast Cancer
2019
·
Lei Wang
, Qiqi Mao
, et al.
·
OncoTargets and Therapy
·
12
PDF
BAY-885, a mitogen-activated protein kinase kinase 5 inhibitor, induces apoptosis by regulating the endoplasmic reticulum stress/Mcl-1/Bim pathway in breast cancer cells
2022
·
Lei Wang
, Xiaochun Ji
, et al.
·
Bioengineered
·
6
PDF
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
2024
·
Feilin Cao
, Zhaosheng Ma
, et al.
·
eLife
·
3
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
2024
·
Feilin Cao
, Zhaosheng Ma
, et al.
·
eLife
·
1
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
2025
·
Feilin Cao
, Zhaosheng Ma
, et al.
·
eLife
Author response: Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
2025
·
Feilin Cao
, Zhaosheng Ma
, et al.
·
eLife
Abstract OT2-14-01: Pyrotinib after trastuzumab-based adjuvant therapy in high-risk early human epidermal growth factor receptor 2-positive breast cancer: a multicenter phase 2 trial
2023
·
Feilin Cao
, Zhaosheng Ma
, et al.
·
Cancer Research
Show more works
View as search
Works count:
7
Citation count:
22
H-index:
3
I10-index:
1
Year
Topic
Type